Therapy

Why?

• Patients with acute coronary syndrome or requiring urgent revascularisation who receive an oral glycoprotein IIb/IIIa inhibitor compared with aspirin are at increased risk of major bleeding and death, but are less likely to undergo urgent revascularisation. ^a
• There is no clear effect on myocardial infarction. ^a

Oral glycoprotein IIb/ IIIa inhibitors increase death and major bleeding

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
acute coronary syndrome or urgent revascularisation a	oral glycoprotein IIb/IIIa inhibitor	aspirin	death at 1-10 months	1.3%	36% (-66% to -13%)	-210 (-600 to -120)
			major bleed at 1-10 months	2.4%	-70% (-95% to -50%)	-59 (-84 to -44)
			urgent revascularisation at 1-10 months	3.6%	22% (13% to 33%)	130 (84 to 220)